Opioid and Cannabinoid Pharmacokinetic Interactions
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00308555 |
Recruitment Status :
Completed
First Posted : March 29, 2006
Results First Posted : July 22, 2013
Last Update Posted : December 9, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pain | Drug: Cannabis | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 24 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Opioid and Cannabinoid Pharmacokinetic Interactions: A Pilot Study |
Study Start Date : | May 2006 |
Actual Primary Completion Date : | March 2009 |
Actual Study Completion Date : | March 2009 |
Arm | Intervention/treatment |
---|---|
Cannabis |
Drug: Cannabis |
- Disposition Kinetics of Morphine and Oxycodone Before and After Cannabis Use [ Time Frame: Day 1, Day 5 ]Pharmacokinetics are measured on Day 1, prior to cannabis use, and again on Day 5, following cannabis use on Days 2, 3, and 4.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Ongoing analgesic therapy with either oxycodone hydrochloride (OxyContin) or morphine sulfate (MS Contin) every 12 hours for chronic pain.
- Eligible subjects will be ≥ 18 years of age with a diagnosis of chronic pain and an estimated survival of greater than six months.
- Subjects must be on a stable dose of opioid medication for at least 2 weeks before enrollment.
- Current other analgesic medications will be maintained during the study. The subject must have been on a stable medication regimen for at least 2 weeks.
-
The following laboratory parameters documented within 45 days prior to study entry:
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 X upper limit of normal (ULN)
- Total bilirubin ≤ 2 X ULN
- Creatinine ≤ 2.0 mg/dL (177 µmol/L)
- All men and women in this study must agree to use adequate birth control during this study. Acceptable barrier birth control methods are a male condom, female condom, diaphragm, or intra-uterine (IUD).
- All women of reproductive potential (who have not reached menopause or undergone hysterectomy, oophorectomy, or tubal ligation) must have a negative urine b-HCG pregnancy test performed before initiating the protocol-specified medication.
- Prior history of use of marijuana. Subjects must have smoked marijuana on at least 6 occasions in their lifetime prior to enrollment.
- Able to understand and follow the instructions of the investigator, including completing the pain intensity rating scales.
- Karnofsky Performance Score >60.
- Able and willing to provide informed consent.
Exclusion Criteria:
- Severe coronary artery disease, uncontrolled hypertension, cardiac ventricular conduction abnormalities, or orthostatic mean blood pressure drop greater than 24 mmHg, severe chronic obstructive pulmonary disease.
- History of renal or hepatic failure.
- Evidence of hepatic, hematological or renal dysfunction based on judgment of physician.
- Active substance abuse (e.g., alcohol or injection drugs).
- Use of smoked marijuana within 30 days of enrollment verified with a urine THC level.
- Neurologic dysfunction or psychiatric disorder severe enough to interfere with assessment of pain or sensory systems.
- Current use of smoked tobacco products or a confirmed cotinine level.
- Women who are pregnant or breast-feeding may not take part in this study.
- Unable to read or speak English.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00308555
United States, California | |
Community Consortium | |
San Francisco, California, United States, 94110 |
Principal Investigator: | Donald I Abrams, M.D. | University of California, San Francisco |
Responsible Party: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT00308555 |
Other Study ID Numbers: |
CC # 064 1R21DA020831-01 ( U.S. NIH Grant/Contract ) |
First Posted: | March 29, 2006 Key Record Dates |
Results First Posted: | July 22, 2013 |
Last Update Posted: | December 9, 2016 |
Last Verified: | October 2016 |
Cannabis Morphine Oxycodone Marijuana chronic pain |